(Q46066104)

19 December 2017

title

Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer (English)

1 reference

19 December 2017

1 reference

Timothy J Daskivich

1

1 reference

19 December 2017

Karim Chamie

2

1 reference

19 December 2017

Lorna Kwan

3

1 reference

19 December 2017

Atreya Dash

4

1 reference

19 December 2017

Sheldon Greenfield

5

1 reference

19 December 2017

Mark S Litwin

6

1 reference

19 December 2017

language of work or name

English

0 references

publication date

16 July 2013

1 reference

19 December 2017

published in

Cancer

1 reference

19 December 2017

volume

119

1 reference

19 December 2017

issue

19

1 reference

19 December 2017

page(s)

3446-3453

1 reference

19 December 2017

Whitmoreisms: memorable quotes from Willet F. Whitmore, Jr, M.D.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Time trends and local variation in primary treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Active surveillance for the management of prostate cancer in a contemporary cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

High-risk prostate cancer: from definition to contemporary management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Overtreatment of men with low-risk prostate cancer and significant comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Outcomes of localized prostate cancer following conservative management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Comorbidity and competing risks for mortality in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Impact of comorbidity on survival among men with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

What are the outcomes of radical prostatectomy for high-risk prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Radical prostatectomy versus observation for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Comorbidity, Treatment and Mortality: A Population Based Cohort Study of Prostate Cancer in PCBaSe Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

7 January 2021

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

7 January 2021

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

7 January 2021

Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

7 January 2021

Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28226

7 January 2021

Identifiers

DOI

10.1002/CNCR.28226

1 reference

19 December 2017

1 reference

19 December 2017